Stephen Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Proud to share results from the TERESA study with Drs. Solange Peters, Joe Y Chang et al:
Real world treatment patterns and outcomes in pts with stage I-II NSCLC who did not undergo resection.
In this Flatiron real world analysis, 40% of pts with stage I-II NSCLC did not undergo surgery – most of those pts received SBRT.
Study of systemic therapy in this pt population represents an important opportunity to improve outcomes and is feasible, based on the size of the real world population.”
“”
You can also read:
PEARLS/KEYNOTE-091: Long-Term Outcomes With Adjuvant Pembrolizumab in NSCLC
